HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Double-blind trial of tiapride versus placebo in patients with sub-perennial idiopathic headache].

Abstract
25 patients with sub-perennial idiopathic headache were given tiapride or a placebo in a double-blind controlled trial, over thirteen weeks. Tiapride was given orally in a dosage of 300 mg per day. Blood was drawn in 10 patients and 10 healthy controls for blood prolactin determination. No significant side-effects were recorded during the trial. Statistical analysis of the results is reported. Tiapride proved effective in reducing the frequency of headache (in 65% of patients), with an improvement rate which was statistically significant in comparison to the placebo. The drug seems to improve the headache index itself, although the difference was not statistically significant; however, the number of patients was small.
AuthorsR Cerbo, M Casacchia, B Boni, R Corona
JournalLa semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris (Sem Hop) Vol. 58 Issue 48 Pg. 2839-44 (Dec 30 1982) France
Vernacular TitleEtude en double aveugle tiapride contre placebo chez des patients souffrant de céphalées essentielles subcontinues.
PMID6302851 (Publication Type: Clinical Trial, English Abstract, Journal Article)
Chemical References
  • Benzamides
  • Placebos
  • Tiapamil Hydrochloride
Topics
  • Adult
  • Benzamides (therapeutic use)
  • Chemical Phenomena
  • Chemistry
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Headache (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Placebos
  • Tiapamil Hydrochloride (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: